$PMCB Officers to Attend 2015 BIO International Convention

This year’s BIO International Convention is termed “The Global Event for Biotechnology.” This Convention is the world’s largest biotechnology gathering. Attendees at the Convention will have the opportunity to reach influential decision makers and high-level executives who come to BIO to discover new “players” in the biotechnology sector, evaluate emerging technologies and even form new partnerships. The 2015 BIO Convention will feature more than 1,700 exhibitors who will occupy approximately 160,000 square feet of floor space. The exhibitors will include: the top 25 pharmaceutical companies, the world’s leading biotech companies, the top 20 Contract Research Organizations and Contract Medical Organizations and more than 300 academic institutions. Major research laboratories, leading consultants, service companies and government agencies will also be represented.

Kenneth L. Waggoner, PharmaCyte Biotech’s Chief Executive Officer, stated, “Attendance at the annual BIO International Convention is really mandatory for a company like ours which is relatively new to the biotechnology arena. This year’s convention will present Dr. Crabtree and me with opportunities to interact with diverse entities from around the world at this single site in Philadelphia. Because of the proximity of so many outstanding companies, organizations and institutions, PharmaCyte Biotech will have the opportunity to develop new relationships and foster already budding ones more easily and quickly than might otherwise be possible.”

About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box^®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech’s treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form. These capsules are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This “targeted chemotherapy” has proven remarkably effective in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.

PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box^® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop “green” approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.

Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte’s ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com